Healthcare / Diagnostics & ResearchLSE
$0.60
+0.02 (+3.45%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 24%
FCF escenarios
weak_data · normalized FCF $1.3B · quality 52.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
66/100
B
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$349M
P/E
0.1x
↓EV/EBITDA
0.1x
↓ROE
37.3%
↑Gross Margin
42.7%
↓Debt/Equity
0.48
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+29.6%
FCF CAGR
—
FCF margin
17.6%
FCF / Net income
1.10x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $7.86B · net income $1.26B · FCF $1.38B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $7.86B | $7.86B | $5.72B | $4.12B | $3.61B |
| Net Income | $1.26B | $1.26B | $1.08B | $510.3M | $541.1M |
| EBITDA | $2.89B | $2.89B | $2.09B | $1.28B | $1.29B |
| EPS | 2.17 | 2.17 | 1.82 | 0.85 | 0.90 |
| Gross Margin | 42.7% | 42.7% | 38.1% | 37.0% | 40.6% |
| Operating Margin | 27.0% | 27.0% | 21.2% | 19.2% | 24.2% |
| Net Margin | 16.1% | 16.1% | 18.8% | 12.4% | 15.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.48 | 0.48 | 0.54 | 0.44 | 0.55 |
| Cash Flow | |||||
| Free Cash Flow | $1.38B | $1.38B | $1.34B | $217.7M | $-100.1M |
| Returns | |||||
| ROE | 37.3% | 37.3% | 39.8% | 19.0% | 25.1% |
| Valuation | |||||
| P/E | 0.12 | 0.12 | 0.25 | 0.42 | 0.73 |
| EV/EBITDA | 0.10 | 0.10 | 0.27 | 0.56 | 0.71 |
| P/B | 0.10 | 0.10 | 0.10 | 0.08 | 0.18 |
| Growth & Yield | |||||
| Revenue Growth | 37.3% | 37.3% | 38.7% | 14.4% | — |
| EPS Growth | 19.2% | 19.2% | 114.1% | -5.6% | — |
| Dividend Yield | 1.5% | 1.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-70.9%
EPS terminal req.
$0.05
Spread vs growth
90.2%
5Y implied EPS CAGR
-50.5%
EPS terminal req.
$0.06
Spread vs growth
69.7%
10Y implied EPS CAGR
-26.2%
EPS terminal req.
$0.10
Spread vs growth
45.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+68.1%
Start / end P/E
0.2x → 0.3x
EPS bridge
1.82 → 2.17
Residual
+7.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.